Skip to content

Study · Randomized controlled trial · n = 34 · 2021

4 results

A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia.

Winzeler B, Sailer CO, Coynel D, Zanchi D, Vogt DR, Urwyler SA, Refardt J, Christ-Crain M

The Journal of clinical investigation1 Oct 2021Cited by 27 (Europe PMC)

PMID34473645 (opens in a new tab)PMCIDPMC8516458 (opens in a new tab)DOI10.1172/jci151800 (opens in a new tab)PepBankPUB-34473645
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, dulaglutide reduced fluid intake versus placebo by 490 mL.

    In plain wordsDulaglutide reduced fluid intake compared with placebo in patients with primary polydipsia.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseFluid intake
    Study

    n = 34

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Appetite and food intake · Kidney and urinary
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Measurements

    Fluid intake difference
    −490 mL
    versus placebo
    Fluid intake on placebo
    2950 mL
    placebo, model estimate
    Fluid intake on dulaglutide
    2460 mL
    dulaglutide, model estimate
    Relative reduction in fluid intake
    17%
    dulaglutide versus placebo

    Source sentences

    Summary
    Patients on dulaglutide reduced their fluid intake by 490 mL (95% CI: -780, -199; P = 0.002), from 2950 mL (95% CI: 2435, 3465) on placebo to 2460 mL (95% CI: 1946, 2475) on dulaglutide (model estimates), corresponding to a relative reduction of 17%.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, dulaglutide reduced urinary output versus placebo.

    In plain wordsDulaglutide reduced urine output compared with placebo in patients with primary polydipsia.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseUrinary output
    Study

    n = 34

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Measurements

    Urinary output difference
    −943 mL
    24-hour urinary output, versus placebo

    Source sentences

    Summary
    Twenty-four-hour urinary output was reduced by -943 mL (95% CI: -1473, -413; P = 0.001).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with primary polydipsia, dulaglutide lowered thirst responses to beverage pictures versus placebo.

    In plain wordsDulaglutide reduced thirst during beverage pictures compared with placebo in patients with primary polydipsia.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseThirst perception
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Nervous system and cognition
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Thirst perception in response to beverage pictures was higher for patients with primary polydipsia than for controls, and lower for patients on dulaglutide versus placebo,
  4. 04HumanRandomized controlled trialMechanism

    In patients with primary polydipsia, functional activity was similar with dulaglutide and placebo.

    In plain wordsBrain activity was similar with dulaglutide and placebo in patients with primary polydipsia.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeFunctional brain activity
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    1.5 mg weekly · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    but functional activity was similar among groups and treatments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02770885

Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

University Hospital, Basel, Switzerlandn = 50Mar 2016 to 7 Oct 2019

Primary Polydipsia

Trial pageClinicalTrials.govUpdated 18 Jan 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.